8-K
filed February 15, 2023, 6:59 PM ET
ticker ASPN
CIK 0001145986
earnings
confidence high
sentiment neutral
materiality 0.70
Aspen Aerogels Q4 revenue $59.6M (+90% YoY); FY2022 revenue $180.4M (+48%), net loss $82.7M
ASPEN AEROGELS INC
2022-FY EPS reported
-$2.10
revenue$180,364,000
- Q4 revenue $59.6M, up 90% YoY from $31.5M.
- Q4 net loss $9.6M ($0.20 per share) vs $16.4M loss ($0.50) in Q4 2021.
- FY2022 revenue $180.4M, up 48% from $121.6M in 2021.
- FY2022 net loss $82.7M ($2.10 per share) vs $37.1M loss ($1.22) in 2021.
- Adjusted EBITDA loss improved to $4.5M in Q4 from $12.2M in prior year.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
ASPEN AEROGELS INC reported the fourth quarter of 2022 results: revenue $59.6 million, net income $9.6 million, EPS $0.20.
- Period
- the fourth quarter of 2022
- Revenue
- $59.6 million
- Net income
- $9.6 million
- EPS
- $0.20
- Result
- reported results
Exact text from the filing
Total revenue for the fourth quarter of 2022 was $59.6 million, compared to $31.5 million in the fourth quarter last year. Fourth quarter net loss was $9.6 million, compared to a net loss of $16.4 million in the fourth quarter of 2021. Net loss per share for the fourth quarter was $0.20, compared to $0.50 in the fourth quarter last year.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
ASPEN AEROGELS INC reported the fiscal year 2022 results: revenue $180.4 million, net income $82.7 million, EPS $2.10.
- Period
- the fiscal year 2022
- Revenue
- $180.4 million
- Net income
- $82.7 million
- EPS
- $2.10
- Result
- reported results
Exact text from the filing
Total revenue for the full year was $180.4 million, compared to $121.6 million in 2021. Net loss for the year was $82.7 million, compared to a net loss of $37.1 million in 2021. Net loss per share for the year was $2.10, compared to $1.22 in 2021.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.